Results 241 to 250 of about 89,537 (296)

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy. [PDF]

Arthritis Rheumatol
Alehashemi S, Buehring B, de Jesus AA, Gaurav S, Rastegar A, Baumgardner A, Friend K, Arisa OT, Figg WD, Fink D, Kuhns DB, Colton B, Peer CJ, Goldbach-Mansky R.   +13 more
europepmc   +1 more source

Mycobacterial cell division arrest and smooth‐to‐rough envelope transition using CRISPRi‐mediated genetic repression systems

FEBS Open Bio, EarlyView.
CRISPRI‐mediated gene silencing and phenotypic exploration in nontuberculous mycobacteria. In this Research Protocol, we describe approaches to control, monitor, and quantitatively assess CRISPRI‐mediated gene silencing in M. smegmatis and M. abscessus model organisms.
Vanessa Point, Wafaa Achache, Janïs Laudouze, Eliana Sepulveda Ramos, Mickaël Maziero, Céline Crauste, Stéphane Canaan, Pierre Santucci   +7 more
wiley   +1 more source

STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL.

Blood
Xu J, Sussman JH, Yang A, Yoshimura S, Hu J, Chen C, Vincent T, Bandyopadhyay S, Li EY, Lim T, Elghawy O, Barsouk A, Karanfilovski D, Wald SL, Chen GM, Wu D, Newman H, Li A, Sun Y, Chen CH, Bernt K, Wood BL, Winter SS, Dunsmore KP, Raetz E, Devidas M, Pounds S, Loh M, Hunger SP, Chiang MY, Diorio C, Di Giacomo D, Pölönen P, Mullighan CG, Yang JJ, Tan K, Teachey DT.   +36 more
europepmc   +1 more source

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. [PDF]

Future Oncol
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, SENTRY investigators.   +10 more
europepmc   +1 more source

Cryptococcosis in a patient with rheumatoid arthritis following glucocorticoid and JAK inhibitor therapy: a case description on stabilization with tocilizumab. [PDF]

Quant Imaging Med Surg
Zhou M, Guan H, Huang Y, Yuan F.
europepmc   +1 more source

Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta-Analysis. [PDF]

Arthritis Care Res (Hoboken)
Sathapanasiri T, Meraz M, Mokri H, K Veettil S, Wijarnpreecha K, Schlesinger N, Kavanaugh A, Chaiyakunapruk N.   +7 more
europepmc   +1 more source

Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment. [PDF]

Nat Commun
Xia X, He C, Xue Z, Wang Y, Qin Y, Ren Z, Huang Y, Luo H, Chen HN, Zhang WH, Huang LB, Shi Y, Bai Y, Cai B, Wang L, Zhang F, Qian M, Zhang W, Shu Y, Yin G, Xu H, Xie Q.   +21 more
europepmc   +1 more source

A single-cell RNA-seq dataset of synovial fluid from rheumatoid arthritis treated with TNF-α/JAK inhibitor. [PDF]

Sci Data
He C, Ren Z, Xia X, Xue Z, Zhang F, Qian M, Shu Y, Yin G, Xie Q, Xu H.   +9 more
europepmc   +1 more source

Correction to “Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors”

Molecular Oncology, EarlyView.
wiley   +1 more source